Treatment of tumor-bearing mice with the SMO inhibitor sonidgeib resulted in reduced tumor growth and significantly improved survival in both the D12M allograft and MG63 and B143 xenograft models, but not in mice with CaOS18, U2OS or SJSA tumors (Fig. 7a, b, Supplementary Fig. 11a, b). The gene discussed is SMO; the disease is neoplasm.